Selective POLQ Inhibitor Compounds for Bioavailable HRD Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for selective POLQ inhibitors that demonstrate good bioavailability and are suitable for dosing, particularly for the treatment of HRD tumors, as POLQ plays a significant role in microhomology-mediated end joining (MMEJ) repair and is associated with therapy resistance in BRCA-related tumors.
Innovation Solution
Development of compounds of formula (I) and their stereoisomers or pharmaceutically acceptable salts, which target POLQ, potentially in combination with PARP inhibitors, to inhibit POLQ activity and enhance the effectiveness of DNA-damaging agents in treating HRD tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If POLQ inhibitors are developed to treat HRD tumors, then therapy resistance is reduced and cell sensitivity to DNA-damaging agents is enhanced, but the inhibitors must achieve good bioavailability and suitable dosing which increases development complexity
Solution Approach 1:
The patent applies parameter changes by systematically modifying molecular parameters of POLQ inhibitors through chemical structure optimization. Specific changes include adjusting molecular weight, logP values, and functional group configurations to achieve optimal bioavailability and dosing characteristics while maintaining POLQ inhibition activity. This allows the compound to satisfy both therapeutic effectiveness requirements and pharmacokinetic constraints.
Solution Approach 2:
The patent employs composite material principles by designing inhibitors that combine multiple functional moieties within a single molecular structure. The compounds integrate DNA polymerase inhibition domains with cellular penetration and binding moieties, creating multifunctional molecules that simultaneously achieve POLQ inhibition, good bioavailability, and suitable dosing characteristics.
2Object-affected harmful factors
If selective POLQ inhibitors are designed to inhibit POLQ activity, then MMEJ repair is blocked and DNA damage accumulation increases, but the inhibitors must demonstrate good bioavailability and be suitable for dosing
Solution Approach 1:
The patent utilizes parameter changes to optimize the physical and chemical properties of POLQ inhibitors. By adjusting molecular weight, lipophilicity (logP), and structural conformations, the compounds achieve optimal balance between DNA damage accumulation capability and pharmacokinetic properties including bioavailability and dosing suitability.
Solution Approach 2:
The patent applies copying principles by deriving inhibitor structures from known polymerase inhibitor frameworks and replicating successful pharmacological features while adapting to POLQ-specific requirements. This allows efficient generation of candidates with both desired biological activity and acceptable pharmacokinetic profiles.
Data Source
AI summary
The specification generally relates to compounds of Formula (I):or a stereoisomer or pharmaceutically salt thereof, wherein G, Ga, Gb, X, Y, R1, R2, Q1, Q2, and Q3 have any of the meanings defined herein, together with compositions containing them and their use in therapy. The compounds are inhibitors of the polymerase, DNA polymerase theta (Polθ or POLQ), and are thereby particularly useful in the treatment of cancer.